A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
Health Heartflow receives FDA clearance for updated plaque analysis platformHealthradar26. September 2025 Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:…
News Heartflow Receives FDA Clearance for Next-Gen AI Plaque Analysis, Expands Cigna CoverageHealthradar23. September 2025 What You Should Know: – Heartflow, a leader in AI technology for coronary artery disease (CAD), has received U.S. Food…
News UnitedHealthcare to Cover Elucid’s PlaqueIQ CTA Plaque Analysis Starting 10/1Healthradar13. August 2025 What You Should Know: – United Healthcare has updated its cardiac imaging guidelines to align with recommendations from radiology benefit…
